Doximity, Inc. (DOCS)
| Market Cap | 4.42B -63.1% |
| Revenue (ttm) | 655.57M +11.2% |
| Net Income | 167.05M -29.0% |
| EPS | 0.84 -27.9% |
| Shares Out | 178.25M |
| PE Ratio | 29.43 |
| Forward PE | 17.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,117,208 |
| Open | 26.62 |
| Previous Close | 26.59 |
| Day's Range | 24.80 - 26.70 |
| 52-Week Range | 17.15 - 76.51 |
| Beta | 1.21 |
| Analysts | Hold |
| Price Target | 29.11 (+17.38%) |
| Earnings Date | Aug 6, 2026 |
About DOCS
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools... [Read more]
Financial Performance
In fiscal year 2026, Doximity's revenue was $644.86 million, an increase of 13.05% compared to the previous year's $570.40 million. Earnings were $196.05 million, a decrease of -12.16%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for DOCS stock is "Hold." The 12-month stock price target is $29.11, which is an increase of 17.38% from the latest price.
News
Doximity downgraded to Underweight from Equal Weight at Wells Fargo
Wells Fargo downgraded Doximity (DOCS) to Underweight from Equal Weight with an unchanged price target of $18. The shares are trading at “compounder multiples” while the company is posting “market-lev...
Doximity stock is reversing post-earnings rally: why that shouldn't surprise you
Doximity (DOCS) stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance. Sti...
Here's Why Doximity Stock Is Flying Today
Shares of Doximity are rocking higher Friday. The reason?
Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last?
While one analyst thinks Doximity has a compelling AI opportunity, another worries that the company could cannibalize its core business of medical networking.
Why Did Doximity (DOCS) Stock Rocket Despite Mixed Q1 Earnings?
Doximity stock saw strong gains on Friday, even after the company posted EPS below Wall Street’s estimates.
Doximity price target raised to $41 from $27 at Needham
Needham analyst Scott Berg raised the firm’s price target on Doximity (DOCS) to $41 from $27 and keeps a Buy rating on the shares. The firm views the company’s Q1…
Doximity price target raised to $38 from $23 at Raymond James
Raymond James raised the firm’s price target on Doximity (DOCS) to $38 from $23 and keeps an Outperform rating on the shares. Doximity delivered a stabilizing Q1 with reaccelerating growth,…
Doximity trading halted, volatility trading pause
09:33 EDT Doximity (DOCS) trading halted, volatility trading pause
Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it
Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to ru...
Doximity AI search momentum building faster than expected, says Morgan Stanley
Morgan Stanley says Doximity (DOCS) posted “a solid beat” in Q1 and provided “mixed guidance,” adding that momentum is building faster than expected for AI search. The firm, which sees…
Doximity price target raised to $40 from $22 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Doximity (DOCS) to $40 from $22 and keeps an In Line rating on the shares.
Doximity price target raised to $30 from $20 at BMO Capital
BMO Capital raised the firm’s price target on Doximity (DOCS) to $30 from $20 and keeps a Market Perform rating on the shares. The company delivered a strong quarter with…
Doximity price target raised to $36 from $30 at Canaccord
Canaccord raised the firm’s price target on Doximity (DOCS) to $36 from $30 and keeps a Buy rating on the shares. The firm said while AI revenue has truly yet…
Doximity Stock Soars Almost 80% After Earnings Miss—It's All About AI
Shares surge, even after the medical networking and telehealth company's earnings miss analysts' targets.
Closing Bell Movers: Doximity soars after quarterly report
Stock futures were mixed following a mostly lower regular session as investors continue to digest another round of corporate earnings and await news out of the Middle East. Economic data…
Doximity Earnings Call Transcript: Q1 2027
Revenue grew 7% year-over-year to $157M, with adjusted EBITDA margin at 48% and strong AI-driven momentum. AI Search and Scribe products are fueling new contracts and deeper client engagement, while guidance for FY27 was raised on robust demand and expanding enterprise adoption.
Doximity Earnings release: Q1 2027
Doximity released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Doximity Quarterly report: Q1 2027
Doximity has published its Q1 2027 quarterly earnings report on August 6, 2026.
Doximity reports Q1 EPS 29c, consensus 30c
Reports Q1 revenue $156.6M, consensus $151.73M. “We’re proud that our clinical AI assistant, Doximity (DOCS) Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered ano...
Doximity sees Q2 revenue $170M-$171M, consensus $171.77M
Sees Q2 adjusted EBTIDA $80.5M-$81.5M
Doximity Announces Fiscal 2027 First Quarter Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 first quarter ended June 30, 2026. ...
Doximity Slides: Investor presentation
Doximity has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.